SARS-CoV-2 IgG antibody responses in rt-PCR-positive cases: first report from India

Girish Chandra Dash†, Debaprasad Pari†, Hari Ram Choudhary†, Annalisha Peter, Usha Kiran Rout, Rashmi Ranjan Nanda, Jaya Singh Kshatri, Srikanta Kanungo, Subrata Kumar Palo, Nityananda Mandal, Sanghamitra Pati* and Debdutta Bhattacharya*

Abstract

Introduction. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibody responses remain poorly understood and the clinical utility of serological testing is still unclear.

Aim. To understand the relationship between the antibody response to SARS-CoV-2 infection and the demographics and cycle threshold (Ct) values of confirmed RT-PCR patients.

Methodology. A total of 384 serum samples were collected from individuals between 4–6 weeks after confirmed SARS-CoV-2 infection and tested for the development of immunoglobulin class G (IgG) against SARS-CoV-2. The Ct values, age, gender and symptoms of the patients were correlated with the development of antibodies.

Results. IgG positivity was found to be 80.2 % (95 % CI, 76.2–84.2). Positivity increased with a decrease in the Ct value, with the highest (87.6 %) positivity observed in individuals with Ct values <20. The mean (±SD) Ct values for IgG positives and negatives were 23.34 (±6.09) and 26.72 (±7.031), respectively. No significant difference was found for demographic characteristics such as age and sex and symptoms and antibody response. The current study is the first of its kind wherein we have assessed the correlation of the RT-PCR Ct with the development of IgG against SARS-CoV-2.

Conclusion. Although Ct values might not have any relation with the development of symptoms, they are associated with the antibody response among SARS-CoV-2-infected individuals.

INTRODUCTION

An outbreak of pneumonia was reported in Wuhan, Hubei Province, PR China in late December 2019 [1], and was later identified to be caused by a novel beta coronavirus closely related to the severe acute respiratory syndrome (SARS) coronavirus (CoV) family – severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) [2]. As of 30 October 2020, more than 51.8 million individuals were infected with SARS-CoV-2, with 1.28 million SARS-CoV-2-associated deaths [3]. The USA, India and Brazil account for the majority of the cases worldwide, with India accounting for 8.2 million cases and 1.2 million deaths [4].

There is a scarcity of information on the antibody response to SARS-CoV-2 infection [5]. SARS-CoV-2 antibodies have been detected from a range of a few days to 3 weeks after onset of symptoms, with the median time reported as 6 days for detectable levels of immunoglobulin class G (IgG) [6–8]. The presence of SARS-CoV-2 IgG antibodies, which is indicative of current or previous infection by SARS-CoV-2, is thought to confer some degree of immunity [9], although there is uncertainty regarding the duration and extent of immunity conferred by them [8, 10, 11].

The present study carried out semi-quantitative SARS-CoV-2 IgG antibody estimation to understand the body’s antibody response in correlation with the severity of
SARS-CoV-2 symptoms, cycle threshold ($C_t$) value, gender and age.

**METHODOLOGY**

**Sample collection**

A subset of 384 individuals were included in the study to evaluate SARS-CoV-2 IgG between 4 and 6 weeks after being confirmed positive for SARS-CoV-2 by real-time reverse transcription-polymerase chain reaction (RT-PCR) from the month of August to October 2020. The $C_t$ values, age, gender and symptoms of the patients were correlated with the development of antibodies. Confirmed coronavirus disease 2019 (COVID-19) cases were defined as those that tested positive for SARS-CoV-2 RNA using RT-PCR testing of combined nasopharyngeal and throat swab (NT) samples. Patients who presented with one or more symptoms, such as fever, breathlessness, cough, fatigue, muscle pain, clogged nasal cavity, sore throat, diarrhoea, loss of taste (anosmia) and loss of smell (ageusia), during the time of RT-PCR testing were considered symptomatic. This study was approved by the Ethics Committee of ICMR-Regional Medical Research Centre, Bhubaneswar. We obtained informed consent from all participants.

**Testing for SARS-CoV-2 IgG**

Semi-quantitative SARS-CoV-2 IgG testing was performed using the ARCHITECT i2000SR platform, which uses chemiluminescent microparticle immunoassay (CMIA) technology for the detection of IgG antibodies against the nucleocapsid protein of SARS-CoV-2 from human serum. The cutoff for antibody response was 1.4 index, above which the sample was considered positive.

**Data analysis**

Data were entered using MS Excel and descriptive statistical analysis was performed using SPSS software (IBM SPSS for Windows, version 24.0, Armonk, NY, USA). Scatterplots were used to demonstrate the relationship between the antibody titre and $C_t$ values. A linear trendline was used to show the correlation. Qualitative data were described using frequencies and percentages and analysed using the chi-square test. Quantitative data were described using mean and standard deviation (sd) and analysed using an independent sample $t$-test.
RESULTS
Out of the total 384 samples collected from SARS-CoV-2 rt-PCR-positive individuals, 80.2% (95% CI, 76.2–84.2) of the samples were found to be positive for antibodies against SARS-CoV-2. The median time of the sample collection was 34 days after confirmatory RT-PCR testing. The mean age of the IgG-positive and -negative individuals was 36.94±11.29 and 36.09±10.18, respectively. IgG positivity was found to be highest (88.3%) in persons aged ≥60 years. No significant difference for antibody response was detected in different age groups ($P=0.437$) (Fig. 1a). The samples were collected predominantly from males [$n=334$ (86.9%)] as opposed to females [$n=50$ (13.1%)]. Males had a greater chance of producing antibodies than females after a SARS-CoV-2 infection, but the difference was found to be statistically insignificant ($P=0.237$) (Fig. 1b). There was no difference in the mean antibody titre values between male and female groups ($P=0.836$). The mean $C_t$ values of symptomatic and asymptomatic patients were 23.48±6.070 and 24.16±6.521, respectively. There was no statistical difference for IgG response between symptomatic and asymptomatic patients ($P=0.754$) (Fig. 1c). The mean ($±sd$) $C_t$ value of the IgG Ab positives was 23.34 ($±6.09$) and in IgG negatives it was 26.72 ($±7.031$). The difference in the mean values was found to be statistically significant ($P<0.001$). The percentage of IgG Ab positives increased with a decrease in the $C_t$ value, which was found to be statistically significant ($P<0.001$) (Fig. 1d). The antibody titre values of the positive individuals mostly (71%) presented between 1.4 to 6.0 index (Fig. 2).

$P$-value of less than 0.05 was considered to be statistically significant.

Fig. 2. Antibody titre vs $C_t$ value for all 384 COVID-19 patients. Red line indicates the reactive titre value of 1.4 index.
DISCUSSION

In this second phase of the COVID-19 pandemic, sero-testing has emerged as a very useful platform to track down the susceptible population. This method is fast and is considered to be complementary to the gold standard RT-PCR test. Most studies have found a surprisingly lower IgG prevalence (<90%) among recovered patients, although a small part of the literature has suggested a higher percentage for the same [8,9]. This anomaly requires a study based on patients’ demographics, infection severity and viral load.

In this study, the antibody response was found to be 80.2% among COVID-19-positive individuals, which had been reported by most of the literature [8,9]. However, a statistically significant correlation was found between Ct value and IgG antibody titre. Antibody titre was found to be directly proportional to a lower Ct value (indicative of higher viral load). Hence, it can be said that higher viral load might lead to the development of a stronger immune response in a SARS-CoV-2-infected individual. Although the kind of immunity exerted by IgG is not yet properly understood, some level of immunity is definitely conferred by IgG, as found in this study. Similar to earlier studies [8], our study showed that the IgG response was greater in males than in females, but the difference was statistically insignificant. The predominantly male population could be a limitation of the current study in determining IgG prevalence in different sexes. There was also no statistically significant association between Ct value and the development of symptoms. One of the earlier studies found that antibody titre cannot be correlated with SARS-CoV-2 disease severity, which can also be corroborated by these data [12].

Without the use of a standard curve using reference materials, the Ct value by itself cannot be interpreted directly as viral load [13], but Ct can be used as being indicative of viral load in an infected individual.

There are additional implications from our study for blood banks wherein donors are screened for antibodies using qualitative antibody tests for convalescent plasma to treat COVID-19 patients. To support a previous diagnosis of SARS-CoV-2, banks wherein donors are screened for antibodies using qualitative antibody tests for convalescent plasma to treat COVID-19 patients. To support a previous diagnosis of SARS-CoV-2 disease severity, which can also be corroborated by these data [12].

CONCLUSION

The current study is the first of its kind wherein we have assessed the correlation of RT-PCR Ct with the development of IgG against SARS-CoV-2. The Ct value might not have any relation with the severity of the disease, but is associated with the antibody response in SARS-CoV-2-infected persons. However, further long-term studies of longitudinal follow-up of a cohort will help in improving our understanding and forming definitive conclusions.

References

1. Huang C, Wang Y, Li X, Ren L, Zhao J, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The Lancet 2020;395:497–506.
2. Wang C, Horby PW, Hayden FG, Gao GF. A novel coronavirus outbreak of global health concern. The Lancet 2020;395:470–473.
3. WHO Coronavirus Disease (COVID-19). Dashboard (Internet). 2020. https://covid19.who.int
4. Ministry of Health and Family Welfare, Home. GOI (Internet). 2020. https://main.mohfw.gov.in
5. Reifer J, Hayum N, Heszkel B, Klagsbald I, Streve VA. SARS-CoV-2 IgG antibody responses in New York City. Diagn Microbiol Infect Dis 2020;98:115128.
6. Xiao AT, Gao C, Zhang S. Profile of specific antibodies to SARS-CoV-2: The first report. J Infect 2020;81:147–178.
7. Zhao J, Yuan Q, Wang H, Liu W, Liao X, et al. Antibody responses to SARS-CoV-2 in patients with novel coronavirus disease Patients With Novel Coronavirus Disease 2019. Clin Infect Dis 2020;71:2027–2034.
8. Wajenberg A, Mansour M, Leven E, Bouvier NM, Patel G, et al. Humoral response and PCR positivity in patients with COVID-19 in the New York City region, USA: An observational study. Lancet Microbe 2020;1:e283–e289.
9. Long Q-X, Liu B-Z, Deng H-J, Wu G-C, Deng K. Antibody responses to SARS-CoV-2 in patients with COVID-19. Nat Med 2020;26:845–848.
10. Azkur AK, Akdis M, Azkur D, Sokolowska M, van de Veen W, et al. Immune response to SARS-CoV-2 and mechanisms of immunopathological changes in COVID-19. Allergy 2020;75:1564–1581.
11. Guo L, Ren L, Yang S, Xiao M, Chang D, et al. Profiling early humoral response to diagnose novel coronavirus disease (COVID-19). Cijn Infect Dis 2020;71:778–785.
12. Tang YW, Schmitz JE, Persing DH, Stratton CW. Laboratory diagnosis of COVID-19: Current issues and challenges. J Clin Microbiol 2020;58:e00512-20.
13. MS Han, Byun JH, Cho Y, Rim JH. RT-PCR for SARS-CoV-2: quantitative versus qualitative. Lancet Infect Dis 2020;20:30424–2.